Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Moon, Hyeong-Gon | - |
dc.contributor.author | Yi, Jae Kyo | - |
dc.contributor.author | Kim, Hee Sung | - |
dc.contributor.author | Lee, Hea Young | - |
dc.contributor.author | Lee, Kyung-Min | - |
dc.contributor.author | Yi, Minju | - |
dc.contributor.author | Ahn, Sookyung | - |
dc.contributor.author | Shin, Hee-Chul | - |
dc.contributor.author | Ju, Ji-hyun | - |
dc.contributor.author | Shin, Incheol | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.date.accessioned | 2022-07-16T12:39:26Z | - |
dc.date.available | 2022-07-16T12:39:26Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2012-12 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/164083 | - |
dc.description.abstract | Background: The clinical implication of Ras/Raf/ERK pathway activity in breast cancer tissue and its association with response to chemotherapy is controversial. We aimed to explore the value of p90RSK phosphorylation, a downstram molecule of the pathway, in predicting chemotherapy response in breast cancer. Methods: The expression of phosphorylated p90RSK (phospho-p90RSK) and chemotherapy response was measured in 11 breast cancer cell lines and 21 breast cancer tissues. The predictive value of phospho-p90RSK was validated in core needle biopsy specimens of 112 locally advanced breast cancer patients who received anthracycline and taxane-based neoadjuvant chemotherapy. Results: In 11 breast cancer cell lines, the relative expression of phospho-p90RSK was inversely correlated with cell survival after doxorubicin treatment (p = 0.021). Similar association was observed in fresh tissues from 21 breast cancer patients in terms of clinical response. In paraffin-embedded, formalin-fixed tissues from core needle biopsy tissues from 112 patients, positive phospho-p90RSK expression was associated with greater tumor shrinkage and smaller post-chemotherapy tumor size. The association between phospho-p90RSK expression and chemotherapy response was more evident in estrogen receptor(ER)-positive tumors. The expression of phosphor-p90RSK did not show a significant relationship with the incidence of pCR. P90RSK silencing using siRNA did not affect the cancer cell's response to doxorubicin, and the expression of phospho-p90RSK was highly correlated with other Ras/Raf/ERK pathway activation. Conclusion: Our results suggest that phospho-p90RSK expression, which reflects the tumor's Ras/Raf/ERK/p90RSK pathway activation can be a potential predictive marker for chemotherapy response in ER-positive breast cancer which needs further independent validation. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.title | Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shin, Incheol | - |
dc.identifier.doi | 10.1186/1471-2407-12-585 | - |
dc.identifier.scopusid | 2-s2.0-84871105827 | - |
dc.identifier.wosid | 000312722000001 | - |
dc.identifier.bibliographicCitation | BMC CANCER, v.12, pp.1 - 9 | - |
dc.relation.isPartOf | BMC CANCER | - |
dc.citation.title | BMC CANCER | - |
dc.citation.volume | 12 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | ESTROGEN-RECEPTOR-ALPHA | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | RSK | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | PHOSPHATASE-1 | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | TAMOXIFEN | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | GROWTH | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | P90RSK | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Predictive marker | - |
dc.subject.keywordAuthor | ERK | - |
dc.subject.keywordAuthor | Estrogen receptor | - |
dc.identifier.url | https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-585 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.